



The Value of IVI to Current and Prospective Member States 2024



www.ivi.int



**International
Vaccine
Institute**

Vaccines Save Lives



**International
Vaccine
Institute**

Index

IVI's Mission and Value for Global Health	04
Deliverables on Urgent Global Health Priorities	05
Accomplishments: OCV, TCV, Global Health	06
IVI in the Global Health Community	08
How to Join IVI	09
The Role of IVI State Parties	10
Funding: Its Uses and Return on Investment	12
Partnerships in Action: How IVI works with Funders	14
IVI Global Council	17
Testimonials from the International Community	18
Appendix 1. Steps to Join IVI as a Member State	20
Appendix 2. A sample letter to IVI requesting the Board of Trustees' approval	21
Appendix 3. A sample Instrument of Accession with the United Nations	22

IVI's Mission and Value for Global Health

The International Vaccine Institute (IVI) is a nonprofit International Organization established in 1997 as an initiative of the United Nations Development Programme (UNDP). We are among the few organizations in the world dedicated to developing vaccines for global health.

Our Mission

Discover, develop and deliver safe, effective and affordable vaccines for global public health.

Discover



New vaccine prototypes in the lab



Disease burdens in the field

Develop



Vaccine production methods and clinical trials



LMIC capacities via training and tech transfers

Deliver



New vaccines for global health



Vaccine introduction and vaccination campaigns

Value of IVI:

Deliverables on Urgent Global Health Priorities




Neglected & poverty-associated diseases

Since 1997, IVI has been dedicated to developing vaccines for the endemic, neglected diseases which plague LMICs and receive no interest from major pharmaceutical companies. IVI has successfully developed and tech transferred vaccines for cholera, typhoid, and dengue to LMIC manufacturers.



Sexual, reproductive, maternal, & child health vaccines

IVI is working globally to reduce the cost of HPV vaccination by proving the efficacy of single dose regimens. IVI is working on vaccines for little-known diseases like Group A Strep, Hepatitis E, and Female Genital Schistosomiasis, which cause severe burden and mortality in women, girls, and infants in LMICs.



Vaccines against AMR

In alignment with the One Health approach, IVI is developing vaccines for pathogens which are increasingly resistant to antibiotics. In addition, IVI's AMR and Vaccines department is engaged in global AMR surveillance, systems strengthening, and LMIC capacity building.



Climate Change Driven Vaccines

Climate change is accelerating the spread of diarrheal diseases and zoonotic pathogens in LMICs and HICs alike. Vaccines play a critical role in mitigating the threats to human health and biodiversity caused by climate change. IVI develops vaccines for diseases which are spreading with the changing climate, such as cholera, typhoid, and chikungunya.




Global Health Security & Pandemic Preparedness

As an implementing partner for CEPI, IVI works on a variety of diseases with pandemic potential. By accelerating LMIC vaccine manufacturing and technology transfers to LMICs, IVI is helping strengthen the global capacity to respond to future pandemics.

IVI Accomplishments

Oral Cholera Vaccine (OCV) Development and Technology Transfer

- Lab to licensure development cost: \$28 million USD over 9 years (2002-2011).
- Seven vaccine technology transfers to manufacturers in five countries (3 ongoing).
- Most affordable OCV on the global market.
- Fills over 95% of the International Coordinating Group cholera vaccine stockpiles.
- Used by WHO, UNICEF, MSF, and IFRC to contain cholera outbreaks.
- Over 128 million doses deployed in vaccination campaigns in over 25 countries.
- Enabled WHO to establish **Ending Cholera- A Global Road Map to 2030**.



Yemen, 2019



Malawi, 2023

OCV Technology Transfer Recipients and Manufacturers



Typhoid Conjugate Vaccine (TCV) Development and Technology Transfer

- Lab to licensure development cost: \$29 million USD over 10 years (2014-2024).
- Two vaccine technology transfers to manufacturers in Korea and Indonesia.
- SK Bioscience's SKYTyphoid became the 3rd TCV to receive WHO prequalification.

TCV Technology Transfer recipients and manufacturers



Korea



Indonesia



Dengue Vaccine technology transfer and clinical trials

IVI transferred the U.S. NIH dengue vaccine technology to Brazil's Instituto Butantan and assisted with phase 2-3 clinical trials. IVI also transferred this vaccine to Vietnam's Vabiotech.



Brazil



IVI Global Health Accomplishments

1,000+

sustainable jobs created at LMIC clinical and epidemiological field sites

1,400+

More than 1,400 published journal articles

1 billion

doses of COVID-19 vaccines committed to COVAX by companies supported by IVI vaccine testing

830+

professionals trained in-person

Through the Global Training Hub for Biomanufacturing

40+

More than 40 clinical trials sponsored by IVI since 2005

12+

vaccine technology transfers of six different vaccines to eight countries

5,000+

Professionals from LMICs trained through IVI's annual International Vaccinology Course

2,100+

professionals trained online

Through the Global Training Hub for Biomanufacturing

IVI: a Synergistic, Non-Redundant Partner in Global Health

Key difference: IVI works directly across the entire vaccine R&D value chain. Other global health organizations only *fund* limited elements of vaccine R&D or acquisition.



Global Health Funders

CEPI

Funds vaccine R&D through Ph. II clinical trials, for pathogens with pandemic potential.



Gavi
The Vaccine Alliance

Funds the purchase of vaccines for routine immunization in LMICs.



The Global Fund
To Fight AIDS, Tuberculosis and Malaria

Funds intervention, infrastructure, policy for HIV, TB, and malaria



Unitaid

Funds scale up access to licensed treatment for HIV, TB, malaria only

How IVI works with key Global Health Partners



- Founding party of IVI with a permanent seat on the IVI Board.
- IVI leads the training courses at the WHO's Global Training Hub for Biomanufacturing in Korea.
- IVI staff sit on six WHO committees.
- IVI helps WHO establish international reference standards for vaccines.
- IVI & WHO codevelop tools for vaccine safety and delivery.
- IVI's oral cholera vaccine fills most of the WHO vaccine stockpile.



- Sibling organizations succeeding the Children's Vaccine Initiative.
- IVI assists Gavi as a Vaccine Investment Strategy (VIS) Advisor, and codeveloped the VIS for both cholera and typhoid vaccines.
- The results of IVI disease surveillance studies help countries apply for Gavi subsidization.

CEPI

- IVI has been a CEPI implementing partner since 2019.
- IVI provides strategic, technical, and scientific support to CEPI for all aspects of vaccine R&D and capacity building.
- CEPI has provided IVI over \$56 million in grants to support vaccine R&D and clinical trials against COVID-19, chikungunya, and Lassa fever.

How to Join IVI



UN Treaty Collection:
IVI Establishment Agreement



Treaty name:

Agreement on the Establishment of the International Vaccine Institute

Depository: Secretary-General of the United Nations.

Chapter IX-3. No. 33836 Multilateral.

IVI is a treaty-based international organization. States and international organizations interested in joining IVI must deposit an instrument of ratification, acceptance, approval, or accession with the UN.

The following steps must be taken to complete the process:

1. The interested state or organization sends a letter to the IVI Board of Trustees (BOT) requesting approval as a new Party.
2. The interested state or organization must then complete the domestic ratification or internal approval process of the IVI Establishment Agreement.
3. The interested state or organization must deposit the appropriate treaty instrument with the UN.



Republic of Korea ratification
December 1996



Finland Accession
August 2020



Bangladesh Ratification
July 2021



UAE Accession March 2022



Rwanda Accession June 2022



Spain Accession June 2022



Thailand Ratification
October 2022



Panama Ratification
March 2023



Kenya Accession
June 2024

The Role of IVI State Parties


IVI is a treaty-based international organization with an independent governance structure. IVI is open to accession by all UN member states and qualified international organizations, and welcomes all to join and contribute to our mission.

Endorse and Inform our Work

By ratifying, or acceding to, the *IVI Establishment Agreement*, State Parties publicly affirm their commitment to achieving a shared vision of a world free from infectious diseases. Through the IVI Global Council, IVI calls upon its State Parties to provide input on IVI's strategy and activities.

Voluntary Funding and Mutual Development

IVI places no financial obligations on its State Parties, but strives to provide a return on investment to its State Funders through a variety of collaborative development opportunities and the advancement of shared global health priorities. State Funders are guaranteed a seat on the IVI Board of Trustees.



Parties to the *IVI Establishment Agreement* are **free to choose** from a menu of engagement options, including:

Benefits to All IVI State Parties



Regular & on-demand briefings and consultations



IVI Global Council Seat
(and Board of Trustees seat, if elected by the IVI Global Council)

Exclusive to Funding Parties



Researcher Fellowships & Training Scholarships



Joint Vaccine R&D and Capacity Building



In-country IVI Office



IVI Board of Trustees Seat

Funding IVI

How does IVI use voluntary core funding from its State Parties?



Facilitating an Independent Research Agenda

Nearly 80% of IVI's revenue comes from restricted project grants. Core funding enables IVI researchers to independently develop new and innovative vaccines.



Recruiting World Class Researchers

Scientists and researchers are the heart of IVI. We strive to hire and retain a diverse team of international experts to fulfill our mission. Core funding makes that possible by supporting competitive salaries and packages.



Sustaining IVI's Laboratories

Core funding helps IVI purchase and maintain the equipment in its state-of-the-art laboratories, directly facilitating the development of new vaccines.



Expanding Global Capacity Building

IVI's global capacity building activities and training courses in LMICs are made possible by voluntary core funding from IVI State Parties.

What is the return on investment to funding states?



De-risk and Accelerate Domestic Vaccine R&D

IVI can use a portion of core funding from a funding state to assist domestic researchers and industry with vaccine R&D and technology transfers. Funders can also request IVI's assistance with vaccine R&D projects of national interest.



Fellowships and Training Opportunities

If requested by a funding state, IVI can provide a limited number of fellowships to domestic researchers to work with IVI at its laboratories or global field sites. Scholarships to the IVI Vaccinology Course can also be arranged for a limited number of domestic students.



Implementation of UN Conventions

Funding states can report their IVI support to the following UN Conventions: *Biological Weapons Convention*, Article 10; *Convention on the Rights of the Child*, Article 24; *International Covenant on Economic, Social and Cultural Rights*, Article 12.2.



Advance the Sustainable Development Goals (SDGs)

IVI benchmarks its projects to the SDGs and contributes quantitative deliverables to SDGs 1, 3, 5, 6, 8, 9, 10, 12, 13, 16, and 17.



Boost the OECD ODA Rating

The OECD's Development Assistance Committee identifies IVI as an Official Development Assistance (ODA)-eligible multilateral organization. Core budget contributions to IVI qualify as an ODA channel of delivery. IVI's ODA channel ID is 47074.

Benefits of Funding IVI: Partnership in Action

Six IVI State Parties currently fund IVI, and the list is growing. Each state's mode of engagement reflects how IVI is able to deliver value across a wide spectrum of domestic and global health priorities.



South Korea

**Annual Contribution:
\$9.2 million USD**

As IVI's host country and biggest funder, South Korea regularly seeks IVI's assistance with Korean global health programs:

- Collaborative vaccine R&D and vaccination campaigns.
 - Vaccine development and technology transfer with Korean manufacturers.
 - Capacity building programs with local universities.
-



Countless lives are still lost to infectious diseases due to lack of available vaccines...The role of IVI as the world's only international organization devoted exclusively to the development of vaccines remains just as important and relevant today.

Sang Chul Park, MD, PhD,
President of the Korea Support Committee for IVI



Sweden

**Annual Contribution:
\$6.8 million USD**

A long-term supporter of IVI and the host country of the IVI European Regional Office, Sweden encourages the adoption of institutional practices aligned with Swedish and European development policies:

- Funding vaccine R&D and LMIC capacity building, with a focus on poverty alleviation.
 - Institutionalization of gender mainstreaming and environmental sustainability.
-



Sweden has supported the Institute since its inception. This is out of a conviction that IVI can contribute to the shared vision of a world free of infectious diseases.

Her Majesty Queen Silvia of Sweden



India

Annual Contribution:
\$500,000 USD

An IVI State Party since 2012 and a funder since 2017, India and IVI collaborate in the following areas:

- Vaccine technology transfers to local manufacturers.
 - IVI Vaccinology Course scholarships.
 - Chikungunya vaccine clinical trials.
 - Disease surveillance and health economics studies.
 - Vaccination campaigns and introductions.
-



We look on this partnership as being potentially a very positive one and a very fruitful one because it will help us work across all stages of the vaccine development pathway.

Dr. Soumya Swaminathan,

Former Chief Scientist, World Health Organization
and former Director General, ICMR



Finland

Annual Contribution:
€500,000 Euros

Finland became an IVI State Party in 2020 as part of its COVID-19 pandemic response and to facilitate the advancement of Finnish development policies and the SDGs. Funding from Finland goes towards:

- Developing vaccines for neglected diseases, especially those affecting the health of women and girls.
 - Training and capacity building in LMICs.
 - COVID-19 vaccine adjuvant development with the University of Helsinki, funding in part by an additional, one-time grant of €500,000 Euros.
-



The commitment to equity in IVI's vision to support developing countries to become free of suffering from infectious diseases is an important value to Finland.

Aino-Kaisa Pekonen,

Minister of Social Affairs and Health of Finland



Thailand

Annual Contribution:
\$100,000 USD

A founding signatory of IVI, Thailand became a State Party and funder in 2022. Funding from Thailand goes towards:

- A fellowship program with Thailand's National Vaccine Institute.
- Vaccine R&D and clinical trial collaboration
- Assisting NVI with the ASEAN Vaccine Security and Self-Reliance (AVSSR) program.



I strongly believe that a robust collaboration between Thailand and IVI will bring us many opportunities for vaccine research and development, and enable stronger immunization support globally.

H.E. Anutin Charnvirakul,
Deputy Prime Minister and Minister of Public Health



Austria

Annual Contribution: €800,000 Euros+
€60,000 in office rent reimbursement

Austria became an IVI State Party in 2024 following the opening of an IVI Country Office in Vienna in 2023. Austria works with IVI to integrate the capacities of Austrian research institutes and biotech firms in vaccine R&D into global health initiatives to combat the spread of infectious diseases and future pandemics.



The Philippines

Annual Contribution: \$20,000 USD

Since 2023, the Philippines has donated to IVI without a formal funding agreement. IVI uses this funding to provide full scholarships to Philippine health professionals to attend the IVI Vaccinology Course.

IVI Global Council

The Global Council is an advisory body through which IVI State Parties engage with IVI’s governance structure.

On the Global Council, IVI State Parties discuss needs and solutions for vaccine research, development, and implementation as well as issues of vaccine equity, access, and capacity-building at global, regional, and national levels.

As an advisory body of IVI, the Global Council advises the Board of Trustees and IVI management on goals and strategies, and elects two non-funding State Parties to the Board.



14 state party representatives of the IVI Global Council attended the inaugural meeting from October 19-20, 2023


IVI Parties (as of June 2024)





The International Vaccine Institute... will surely help UNICEF achieve its goal of immunizing all the world's children against deadly diseases.

Kofi Annan, 7th Secretary-General of the United Nations



We are delighted to reaffirm our partnership with IVI, following several years of fruitful collaboration to advance vaccine R&D for better global health...this ongoing partnership will play an important role in our work to ensure the world is better prepared to fight future outbreaks

Dr. Richard Hatchett, CEO of CEPI



It's been amazing to see the journey [IVI] has taken. Founded to help bring new vaccines to developing countries, the IVI has lived up to its mission. We look forward to working with IVI ... to bring exciting new technologies to developing countries throughout the world

Dr. Seth Berkley, former CEO of GAVI



Welcoming the IVI Office in Africa is another step towards Africa's self-sufficiency in building a sustainable health sector and [Rwanda] is proud to be the headquarters of this organization.

**Hon. Dr Sabin Nsanzimana,
Minister of Health of Rwanda**



“

Ban Ki-moon,**8th Secretary General of the United Nations, addressing IVI member states**

There are still neglected diseases [for which] there is no investment. This is what I call an injustice. Many people still die from vaccine-preventable diseases unnecessarily. It pains me...The dynamic work of the IVI has amplified the essential role of vaccines in achieving the UN's global goals such as ending extreme poverty, confronting health implications related to climate change, and promoting peace and living with dignity for all people, particularly the world's most vulnerable group of people...I really thank you all for your support. Moral support, political support, but the most important support would be financial...We really count on your continuing support.



For inquiries and additional information, please contact:

IVI Global Affairs and Communication Team

Ms. Youngmi Cho,
Head of Global Affairs and Communications
Tel: +82 2 881 1439, E-mail: Youngmi.cho@ivi.int

Mr. Colin McCann,
Global Affairs Manager
Tel: +43 017-172-8491, Email: Colin.McCann@ivi.int

Appendix 1. Steps to Join IVI as a Member State

In order to become a party to the IVI Establishment Agreement, the following steps must be taken:

1. Submit a letter to IVI requesting the Board of Trustees' approval to become a party to IVI Establishment Agreement.
2. Upon receiving approval from the IVI Board of Trustees, the interested state or entity must deposit an Instrument of Accession with the United Nations.

The instructions for depositing the instrument are as follows:

1. Prepare the instrument of accession in accordance with UN standards.
2. Deliver the instrument by hand, mail or fax to the Treaty Section of the United Nations, preferably including translation into English or French, where appropriate. The contact information for the Treaty Section is as follows:

Treaty Section
Office of legal Affairs
United Nations
New York, NY 10017
USA

- **Tel:** 1-212 963 5047
- **Fax:** 1-212-963-3693
- **Email:** treaty@un.org ; TreatyRegistration@un.org

Note: If the instrument is faxed to the Treaty Section, deliver the original instrument to the Treaty Section as soon as possible thereafter.

3. Notify IVI of the deposit and provide a copy of the instrument.

Appendix 2. A sample letter to IVI requesting the Board of Trustees' approval

[Date]

Jerome H. Kim, MD
Director General
International Vaccine Institute
1 Gwanak-gu, Gwanak-ro
Seoul 08826 Korea
Jerome.Kim@ivi.int

Request for Approval as a Member of the International Vaccine Institute

Dear Dr. Kim,

The Government [or Ministry of Foreign Affairs or Health] of [Name of Country or Body] has elected to become a member of the International Vaccine Institute and requests consideration of its accession as a Party to the Establishment Agreement of the International Vaccine Institute. Please bring this request forward to the IVI Board of Trustees for consideration, and we look forward to your positive response.

[Name of Country or Body] sees value in an international organization devoted to the discovery, development and delivery of safe, effective and affordable vaccines. We hope through our participation in this endeavor that both parties will realize a world where effective vaccines make an impact on global health.

Upon approval of this request by the IVI Board of Trustees, [Name of Country or Body] will deposit a Letter of Accession to the Treaty Section of the United Nations through its Permanent Mission to the United Nations in New York.

Sincerely,
[Signature]*

Appendix 3. A sample Instrument of Accession with the United Nations

INSTRUMENT OF ACCESSION ACCESSION

.....

WHEREAS the “Agreement on the establishment of the International Vaccine Institute”, was concluded at the Headquarters of the United Nations, New York on 28 October, 1998,

NOW THEREFORE I, [name and title of the Head of State, Head of Government or Minister for Foreign Affairs] declare that [Name of Country or Body], having considered the above-mentioned agreement, accedes to the same and undertakes faithfully to perform and carry out the stipulations therein contained.

IN WITNESS WHEREOF, I have signed this instrument of accession at [the place] on [date].

[Signature]



**International
Vaccine
Institute**



+82-2-872-2801



iviinfo@ivi.int



IVI Headquarters

International Vaccine Institute SNU Research Park, 1
Gwanak-ro, Gwanak-gu, Seoul, 08826 Korea

IVI Europe Regional Office

Berzelius Väg 8, 171 65 Solna
Stockholm, Sweden